Regulation of insulin-like growth NF-κB proteasome system in endometrial cancer

Molecular Biology

Volumn 46, Issue 3, 2012, Pages 407-413

  Spirina, L V ^a   Bochkareva, N V ^a   Kondakova, I V ^a   Kolomiets, L A ^a   Shashova, E E ^a   Koval', V D ^a   Chernyshova, A L ^a   Asadchikova, O N ^a  

^a CANCER RESEARCH INSTITUTE   (Russian Federation)

Author keywords

endometrial cancer; insulin like growth factors; NF B; proteasome

Indexed keywords

EID: 84862315989     PISSN: 00268933     EISSN: 16083245     Source Type: Journal    
DOI: 10.1134/S0026893312020173     Document Type: Article

References (30)

1. Firth S. M., Baxter R. C. 2002. Cellular action of the insuline-like growth factor binding proteins. Endocrine Rev. 23(6), 824-854.
2. Bochkareva N. V., Kolomiets L. A., Kondakova I. V., Chernyshova A. L. 2009. Role of insulin-like growth factors and their binding proteins in pathogenesis and prognosis of endometrial cancer. Ross. Onkol. Zh. 3, 46-50.
3. Juvekar A., Manna S., Ramaswami S., Chang T. P., Vu H. Y., Ghosh C. C., Celiker M. Y., Vancurova I. 2011. Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB-dependent transcription and induction of apoptosis in CTCL. Mol. Cancer Res. 9(2), 183-194.
4. Kostadinova R. M., Nawrocki A. R., Frey F. J., Frey B. M. 2005. Tumor necrosis factor alpha and phorbol 12-myristate-13-acetate down-regulate human 11-beta-hydroxysteroid dehydrogenase type 2 through p50/p50 NF-kappaB homodimers and Egr-1. FASEB J. 19(6), 650-652.
5. Marui N., Medford R. M., Ahmad M. 2005. Activation of RelA homodimers by tumor necrosis factor alpha: A possible transcriptional activator in human vascular endothelial cells. Biochem. J. 390, 317-324.
6. Baldwin A. S. 1996. The NF-kappa B and I-kappa B proteins: New discoveries and insights. Annu. Rev. Immunol. 14, 649-683.
7. Muller M., Morotti A., Ponzetto C. 2002. Activation of NF-B is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol. Cell. Biol. 22(4), 13012-13017.
8. Cramer M., Nagy I., Murphy B. J., Gassmann M., Hottiger M. O., Georgiev O., Schaffner W. 2005. NFkappaB contributes to transcription of placenta growth factor and interacts with metal responsive transcription factor-1 in hypoxic human cells. Biol. Chem. 386(9), 865-872.
9. Crisostomo P. R., Wang Y., Markel T., Wang M., Lahm T., Meldrum D. R. 2008. Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by NF kappa B-but not JNK-dependent mechanism. Am. Physiol. Cell. Physiol. 294(3), 675-682.
10. Emmerich N. P., Nussbaum A. K., Stevanovic S., Priemer M., Toes R. E., Rammensee H. G., Schild H. 2000. The human 26S and 20S proteasomes generate overlapping but different sets of peptide fragments from a model protein substrate. J. Biol. Chem. 275. 21140-21148.
11. Sorokin A. V., Kim E. R., Ovchinnikov L. P. 2009 Proteasome system of protein degradation and processing. Usp. Biol. Khim. 49, 3-76.
12. Almond J. B., Cohen G. M. 2002. The proteasome: A novel target for cancer chemotherapy. Leukemia. 16(4), 433-443.
13. Satoh S., Yanagita T., Maruta T., Nemoto T., Yoshikawa N., Kobayashi H., Tono T., Wada A. 2008. Proteasomal degradation of IRS-2, but not IRS-1 by calcineurin inhibition: Attenuation of insulin-like growth factor-I-induced GSK-3beta and ERK pathways in adrenal chromaffin cells. Neuropharmacology. 55(1), 71-79.
14. Girnita L., Girnita A., Larsson O. 2003. Mdm2-dependent ubiguination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 100, 8247-8252.
15. Resch Z. T., Oxvig C., Bale L. K., Conover C. A. 2006. Stress-activated signaling pathways mediate the stimulation of pregnancy-associated plasma protein-A expression in cultured human fibroblasts. Endocrinology. 147(2), 885-890.
16. Conner J. R., Smirnova I. I., Moseman A. P., Poltorak A. 2010. IRAK1BP1 inhibits inflammation by promoting nuclear translocation of NF-kappaB p50. Proc. Natl. Acad. Sci. U. S. A. 107(25), 11477-11482.
17. Bershtein L. M. 2004. Onkoendokrinologiya: traditsii, sovremennost' i perspektivy (Oncoendocrinology: Traditions, Current State, and Prospects). Moscow: Nauka.
18. McCampbell A. S., Broaddus R. R., Loose D. S., Davis P. J. A. 2006. Overexpression of the insuline-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin. Cancer Res. 12, 6373-6378.
19. Abramova E. B., Astakhova T. M., Erokhov P. A., Sharova N. P. 2006. Multiple forms of proteasomes and approaches to their separation. Biol. Bull. 31(2), 115-120.
20. Ben-Shahar S., Komlosh A., Nadav E., Shaked I., Ziv T., Admon A., DeMartino G. N., Reiss Y. 1999. 26S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate. J. Biol. Chem. 274(31), 21963-21972.
21. Shashova E. E., Kondakova I. V., Slonimskaya E. M., Glushchenko S. A. 2010. In: Vseros. nauchno-prakticheskaya konf. s mezhdunarodnym uchastiem "Aktual'nye voprosy onkologii" (Current Problems in Oncology: Proc. All-Russia Sci.-Pract. Conf. with International Participation). Krasnoyarsk, pp. 226-227.
22. Spirina L. V., Kondakova I. V., Usynin E. A., Kolomiets L. A., Vintizenko S. I., Bochkareva N. V., Chernyshova A. L. 2009. Proteasome activity in tissues of differently localized malignant tumors. Sib. Onkol. Zh. 5, 43-48.
23. Li C., Kiran M. 2005. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res. 65, 5599-5606.
24. Xie Y. 2010. Structure, assembly and homeostatic regulation of the 26S proteasome. J. Mol. Cell Biol. 2, 308-317.
25. Xu H., Ju D., Jarois T., Xie Y. 2008. Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells. Breast Cancer Res. Treat. 107, 267-274.
26. Dolcet X., Llobet D., Encinas M., Pallares J., Cabero A., Schoenenberger J. A., Comella J. X., Matias-Guiu X. 2006. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J. Biol. Chem. 281(31), 22118-22130.
27. Perkins N. D., Gilmore T. D. 2006. Good cop, bad cop: The different faces of NF-kappaB. Cell Death Diff. 5, 759-772.
28. Pallares J., Martinez-Guitarte J. L., Dolcet X., Llober D., Rue M., Palacoos J., Prat J., Matias-Guiu X. 2004. Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J. Pathol. 204(5), 569-577.
29. Sixt S. U., Peters J. 2010. Extracellular alveolar proteasome: Possible role in lung injury and repair. Am. Thoracic Soc. 7, 91-96.
30. Heubner M., Wimberger P., Dahlmann B., Kasimir-Bauer S., Kimmig R., Peters J., Wohlschlaeger J., Sixt S. U. 2011. The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. Gynecol. Oncol. 120(2), 233-238.